Effect of metformin and rosiglitazone on lipid metabolism in HIV infected patients receiving protease inhibitor containing HAART

Acta Dermatovenerologica Alpina, Pannonica et Adriatica

Volumn 14, Issue 3, 2005, Pages 99-105

  Tomažič, Janez ^a   Karner, Primož ^a   Vidmar, Ludvik ^a   Matičič, Mojca ^a   Sharma, Prem M ^b   Janež, Andrej ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

HIV; Metformin; Protease inhibitors; Rosiglitazone; Serum lipids

Indexed keywords

AGRULAB; DIDANOSINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; INSULIN; LAMIVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PROTEINASE INHIBITOR; ROSIGLITAZONE; STAVUDINE; TRIACYLGLYCEROL; ZIDOVUDINE;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; HIV INFECTIONS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIPIDS; MALE; METFORMIN; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEASE INHIBITORS; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 24744450132     PISSN: 13184458     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-60.
2. The CASCADE Collaboration. Survival after introduction of HAART in people with known duration of HIV-1 infection. Lancet 2000; 355: 1158-9.
3. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction and natural course of HIV-1 protease inhibitor associated lipodystrophy, hyperlipidaemia and diabetes mellitus: a cohort study. Lancet 1999; 353: 2093-9.
4. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D, and the Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17: 2479-86.
5. Braitstein P, Yip B, Heath KV, et al. Interventional cardiovascular procedures among HIV-infected individuals on antiretroviral therapy 1995-2000. AIDS 2003; 17: 2071-2075.
6. Grunfeld C. HIV protease inhibitors and glucose metabolism. AIDS 2002; 16: 925-6.
7. Fantoni M, Del Borgo C, Autore C. Evaluation and management of metabolic and coagulative disorders in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 2003; 17 (Suppl1): S162-9.
8. Mulligan K, Grunfeld C, Tai VW. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000; 23: 35-43.
9. Dubé MP, Edmonson-Melancom H, Qian D, et al. Prospective evaluation of the effect of initiating indinavir-based therapy on insulin sensitivity and B-cell function in HIV-infected patients. J AIDS 2001; 27: 130-4.
10. Nolan D, Mallal S. Getting to the HAART of insulin resistance. AIDS 2001; 15: 2037-41.
11. Murata H, Hruz PW, Mueckler M. Mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000; 275: 251-4.
12. Nolte LA, Yarasheski KE, Kawanaka F, Fisher J, Le N, Holloszy JO. The HIV protease inhibitor indinavir decreases insulin- and contraction-stimulated glucose transport in skeletal muscle. Diabetes 2001; 50: 1397-401.
13. Schutt M, Meier M, Meyer M, Klein J, Aries SP, Klein HH. The HIV-1 protease inhibitor indinavir impairs insulin signalling in HepG2 hepatoma cells. Diabetologia 2000; 43: 1145-8.
14. Dubé MP. Disorders of glucose metabolism in patients infected with human immunodeficiency virus. Clin Infect Dis 2000; 31: 1467-75.
15. Bodasing N, Fox R. HIV-associated lipodystrophy syndrome: assessment and management. J Infect 2003; 46: 87-93.
16. Grinspoon S. Mechanisms and strategies for insulin resistance in acquired immune deficiency syndrome. Clin Infect Dis 2003; 37 (Suppl 2): S85-90.
17. Mooser V. Atherosclerosis and HIV in the highly active antiretroviral therapy era: towards an epidemic of cardiovascular disease. AIDS 2003; 17 (Suppl 1): S65-9.
18. Vittecoq D, Escaut L, Chironi G, et al. Coronary heart disease in HIV-infected patients in the highly active antiretroviral treatment era. AIDS 2003; 17 (suppl 1): S70-6.
19. van der Valk M, Bisschop PH, Romijn JA, et al. Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways. AIDS 2001; 15: 2093-100.
20. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrphy, hyperlipidemia, and insulin resistance. Lancet 1998; 352: 1881-3.
21. Sniderman AD, Cianflone K, Arner P, Summers LKM, Frayn KN. The adipocyte, fatty acid trapping, and atherogenesis. Arterioscler Thromb Vasc Biol 1998; 18: 147-51.
22. Purnell JQ, Zambon A, Knopp RH, Pizzuti DJ, Achari R, Leonard JM. Effect of ritonavir on lipids and post-heparin lipase in normal subjects. AIDS 2000; 14: 51-7.
23. Saint-Marc T, Touraine JL. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy. AIDS 1999; 13: 1000-2.
24. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA 2000; 284: 472-7.
25. Walli R, Michl GM, Muhlbayer D, et al. Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor associated diabetes mellitus. Res Exp Med 2000; 199: 253-62.
26. Sutinen J, Hakkinen AM, Westerbacka J, et al. Rosiglitazone in the treatment of HAART associated lipodystrophy: a randomized double-blind, placebo-controlled study. Antiviral Ther 2003; 8 (3): 199-207.
27. Gelato MC, Mynarcik DC, Quick JL, et al. Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study. J AIDS 2002; 31: 163-70.